A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

A federal judge’s ruling restricts compounding pharmacies from producing generic Zepbound, sparking concerns over ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...